Showing posts with label enzalutamide. Show all posts
Showing posts with label enzalutamide. Show all posts

Tuesday, April 9, 2013

In a retrospective review of Lung cancers , use of Beta blockers may provide survival advantage

*In a retrospective review of Lung cancers , use of Beta blockers may provide survival advantage.

*Ruloxitinib, still the success story in JAK driven diseases.  For JAK driven disease to be seen more in Hematologic malignancy, the receptors for hematologic growth hormones must be stimulated.
COMFORT-1 showed 41.9% of patients on Ruxolitinib had spleen reduction  but in COMFORT-2, only 28% had spleen reduction by week 48.

The JAK inhibitors are now being tried in Pancreatic cancers!

*Obstruction to Cure is not only found in limitation of progress in science, but in man made complications such disparities in funding availability and managed care obstruction to access to known medications!  Cure escapes us for our own doing, in a summary!

*In Breast Cancer, Inhibitors to CD4,6 are proving to be a new approach when given with Letrozole

*In Prostate cancer don't be too eager to use Steroids with enzalutmide.  Steroids may "activate androgen receptors promoting the cancer".   I should confess this point is a bit controversial since that's what we do, stimulate to better kill with chemotherapy (Taxotere-Cabazitaxel).  But the logic may not work for another hormone used for killing.

*In Tivo-1,
they found no survival advantage for TIVOZANIB Vs Sorafenib in patient with Renal Cancer.
Tivozanib is said to be more potent and selective for VEGF receptors!  PFS was superior though with TIVO!

*Check this out!  The global multikinase inhibitor Regorafenib (blocks VEGFR1,KIT,TIE2,PDGFR and RET) got approved for GIST.  patients received 160 mg PO daily x21 Q28. Watch for fatigue hand foot sundrome diarrhea, loss of appetite,HTN,weight loss,rash and fever.  and being an anti-VEGF, bleeding and intestinal perforation of course!  rare cases of Coronary attacks!
*New kid on the block, RAMUCIRUMAB TRIED IN GASTRIC CANCER!

(READ TARGETED THERAPY NEWS)

Friday, December 21, 2012

2012 New Drug Approvals
From Medscape Oncology
Cancer Beats All Other Fields for 2012 New Drug Approvals
1. Axitinib (Inlyta, Pfizer)
Drug monograph on Medscape Reference

FDA Approves Axitinib for Advanced Renal Cell Cancer
Medscape News, January 30, 2012
2. Vismodegib (Erivedge, Genentech)
Drug monograph on Medscape Reference

FDA Approves Vismodegib for Advanced Basal Cell Carcinoma
Medscape News, January 30, 2012
3. Pertuzumab (Perjeta, Roche)
Drug monograph on Medscape Reference

Pertuzumab Approved for HER2 Breast Cancer
Medscape News, June 11, 2012
4. Carfilzomib (Kyprolis, Onyx Pharmaceuticals)
Drug monograph on Medscape Reference

Carfilzomib Receives FDA Nod for Multiple Myeloma
Medscape News, July 20, 2012
5. Ziv-aflibercept (Zaltrap)
Drug monograph on Medscape Reference

Aflibercept Approved for Colorectal Cancer in the US
Medscape News, August 3, 2012
6. Enzalutamide (Xtandi, Astellas/Medivation)
Drug monograph on Medscape Reference

Enzalutamide Gets FDA Nod for Late-Stage Prostate Cancer
Medscape News, August 31, 2012
7. Bosutinib (Bosulif, Pfizer)
Drug monograph on Medscape Reference

A 4th Option for CML: FDA Grants Approval for Bosutinib
Medscape News, September 4, 2012
8. Regorafenib (Stivarga, Bayer)
Drug monograph on Medscape Reference

FDA Approves Regorafenib for Metastatic Colorectal Cancer
Medscape News, September 27, 2012
9. Omacetaxine mepesuccinate (Synribo, Teva Pharmaceuticals)
Drug monograph on Medscape Reference

FDA Approves New Drug for Chronic Myelogenous Leukemia
Medscape News, October 26, 2012
10. Cabozantinib (Cometriq, Exelixis)
Drug monograph on Medscape Reference

FDA Approves Cabozantinib for Medullary Thyroid Cancer
Medscape News, November 29, 2012
11. Ponatinib (lclusig, Ariad)
Drug monograph on Medscape Reference

FDA Approves Ponatinib for Rare Leukemias
Medscape News, December 14, 2012

Other Approvals
The FDA approved another 3 agents for use in cancer patients this year, either for supportive care or for imaging.


1. Glucarpidase (Voraxaze, BTG International)
Drug monograph on Medscape Reference

FDA Approves Glucarpidase to Reduce Toxic Methotrexate Levels
Medscape News, January 17, 2012

2. Tbo-filgrastim (TevaGrastim, Teva Pharma) - a biosimilar to Neupogen, Amgen
Drug monograph on Medscape Reference

FDA Approves Tbo-Filgrastim for Neutropenia
Medscape News, August 29, 2012

3. FDA Approves PET Imaging Agent for Prostate Cancer
Medscape News, September 12, 2012